Peptides effective for inhibiting cholesterol aggregation in the vascular wall
- Details
- Category: Projects
-
19 Jun 2019
A work demonstrates that peptides derived from a LRP1 receptor sequence are very effective inhibiting the aggregation of LDL (low density lipoprotein, also called 'bad' cholesterol) that takes place in the vascular wall during development of atherosclerosis.
Only the introduction is translated
Low cost and reusable wearable sensors
- Details
- Category: Technological offers
-
18 Jun 2019
Scientists at the CSIC have developed new portable and non-invasive sensors for monitoring biomarkers such as glucose, lactate or alcohol. They are based on wireless electro chromic and electrochemical sensors, and they can be used to detect metabolites in biological fluids, either human fluids (sweat, urine…) or in fluids derived from food products (e.g., leaking).
A metabolite from a drug against diabetes, a possible treatment for neurodegenerative diseases
- Details
- Category: Projects
-
06 Jun 2019
MIN-102, a metabolite from a drug against diabetes, could be useful for treating some neurodegenerative diseases, as scientists think. To confirm this hypothesis, a project has been launched with the involvement of the CSIC’s Instituto de Investigaciones Biomédicas de Barcelona, the Hospital Universitari 'Sant Joan de Déu' and the University of Lleida. The research project is led by the company Mynorix Therapeutics.
Modulating compounds of KChIP2 and its use for the treatment of cardiovascular pathologies
- Details
- Category: Technological offers
-
18 Jun 2019
CSIC and UAM have developed compounds that positively modulate protein-protein interactions that involve KChIP2protein. Industrial partners from the pharmaceutical industry are being sought to collaborate through a patent licence agreement.
Preclinical trial with efavirenz for the treatment of Niemann-Pick C disease
- Details
- Category: Technological offers
-
05 Apr 2019
A team of scientists from the Centro de Biología Molecular Severo Ochoa (CMBSO-CSIC) has developed a new treatment for the Niemann-Pick disease type C (NPC) based on the drug efavirenz. The study is at the preclinical stage.